200 related articles for article (PubMed ID: 16166607)
21. Cognitive neuroscience and schizophrenia: translational research in need of a translator.
Cohen JD; Insel TR
Biol Psychiatry; 2008 Jul; 64(1):2-3. PubMed ID: 18549873
[No Abstract] [Full Text] [Related]
22. Procedures and methods of benefit assessments for medicines in Germany.
Bekkering GE; Kleijnen J
Eur J Health Econ; 2008 Nov; 9 Suppl 1():5-29. PubMed ID: 18987905
[TBL] [Abstract][Full Text] [Related]
23. Developing predictive animal models and establishing a preclinical trials network for assessing treatment effects on cognition in schizophrenia.
Floresco SB; Geyer MA; Gold LH; Grace AA
Schizophr Bull; 2005 Oct; 31(4):888-94. PubMed ID: 16079387
[TBL] [Abstract][Full Text] [Related]
24. A summary of the FDA-NIMH-MATRICS workshop on clinical trial design for neurocognitive drugs for schizophrenia.
Buchanan RW; Davis M; Goff D; Green MF; Keefe RS; Leon AC; Nuechterlein KH; Laughren T; Levin R; Stover E; Fenton W; Marder SR
Schizophr Bull; 2005 Jan; 31(1):5-19. PubMed ID: 15888422
[TBL] [Abstract][Full Text] [Related]
25. Social cognition in schizophrenia: recommendations from the measurement and treatment research to improve cognition in schizophrenia new approaches conference.
Green MF; Olivier B; Crawley JN; Penn DL; Silverstein S
Schizophr Bull; 2005 Oct; 31(4):882-7. PubMed ID: 16135561
[TBL] [Abstract][Full Text] [Related]
26. [Functional outcome in schizophrenia: relation to the MATRICS consensus cognitive battery].
Sumiyoshi C
Nihon Shinkei Seishin Yakurigaku Zasshi; 2011 Nov; 31(5-6):251-7. PubMed ID: 22256615
[TBL] [Abstract][Full Text] [Related]
27. An industry perspective on the NIMH consensus statement on negative symptoms.
Alphs L
Schizophr Bull; 2006 Apr; 32(2):225-30. PubMed ID: 16469940
[TBL] [Abstract][Full Text] [Related]
28. [Essentials of neurocognitive assessment in clinical research].
Sumiyoshi T
Nihon Shinkei Seishin Yakurigaku Zasshi; 2012 Jun; 32(3):149-53. PubMed ID: 22834104
[TBL] [Abstract][Full Text] [Related]
29. The FDA-NIMH-MATRICS guidelines for clinical trial design of cognitive-enhancing drugs: what do we know 5 years later?
Buchanan RW; Keefe RS; Umbricht D; Green MF; Laughren T; Marder SR
Schizophr Bull; 2011 Nov; 37(6):1209-17. PubMed ID: 20410237
[TBL] [Abstract][Full Text] [Related]
30. How to anticipate the assessment of the public health benefit of new medicines?
Massol J; Puech A; Boissel JP;
Therapie; 2007; 62(5):427-35. PubMed ID: 18206104
[TBL] [Abstract][Full Text] [Related]
31. [Procedures and methods of benefit assessments for medicines in Germany].
Bekkering GE; Kleijnen J
Dtsch Med Wochenschr; 2008 Dec; 133 Suppl 7():S225-46. PubMed ID: 19034813
[TBL] [Abstract][Full Text] [Related]
32. [Cognitive deficits in schizophrenia and other psychotic disorders].
Fagerlund B; Glenthøj BY
Ugeskr Laeger; 2008 Nov; 170(46):3770-2. PubMed ID: 19014728
[TBL] [Abstract][Full Text] [Related]
33. Using the MATRICS to guide development of a preclinical cognitive test battery for research in schizophrenia.
Young JW; Powell SB; Risbrough V; Marston HM; Geyer MA
Pharmacol Ther; 2009 May; 122(2):150-202. PubMed ID: 19269307
[TBL] [Abstract][Full Text] [Related]
34. New paradigms for treatment development.
Stover EL; Brady L; Marder SR
Schizophr Bull; 2007 Sep; 33(5):1093-9. PubMed ID: 17673495
[TBL] [Abstract][Full Text] [Related]
35. [Development of antituberculous drugs: current status and future prospects].
Tomioka H; Namba K
Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
[TBL] [Abstract][Full Text] [Related]
36. The MATRICS consensus cognitive battery (MCCB): co-norming and standardization in Spain.
Rodriguez-Jimenez R; Bagney A; Garcia-Navarro C; Aparicio AI; Lopez-Anton R; Moreno-Ortega M; Jimenez-Arriero MA; Santos JL; Lobo A; Kern RS; Green MF; Nuechterlein KH; Palomo T
Schizophr Res; 2012 Feb; 134(2-3):279-84. PubMed ID: 22192501
[TBL] [Abstract][Full Text] [Related]
37. NIMH-MATRICS survey on assessment of neurocognition in schizophrenia.
Kern RS; Green MF; Nuechterlein KH; Deng BH
Schizophr Res; 2004 Dec; 72(1):11-9. PubMed ID: 15531403
[TBL] [Abstract][Full Text] [Related]
38. Predicting drug efficacy for cognitive deficits in schizophrenia.
Hagan JJ; Jones DN
Schizophr Bull; 2005 Oct; 31(4):830-53. PubMed ID: 16177277
[TBL] [Abstract][Full Text] [Related]
39. Mental health advocates complain about NIMH priority for AIDS. National Institute of Mental Health.
AIDS Policy Law; 2000 Jan; 15(1):5. PubMed ID: 11367224
[TBL] [Abstract][Full Text] [Related]
40. How should DSM-V criteria for schizophrenia include cognitive impairment?
Keefe RS; Fenton WS
Schizophr Bull; 2007 Jul; 33(4):912-20. PubMed ID: 17567627
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
